Director Ault Milton C Iii bought $93 worth of shares (25 units at $3.74) (SEC Form 4)

$ALZN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ALZN alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
AULT MILTON C III

(Last) (First) (Middle)
11411 SOUTHERN HIGHLANDS PARKWAY
SUITE 240

(Street)
LAS VEGAS NV 89141

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc. [ ALZN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/31/2024 P 25 A $3.7368(1) 77,193 I By Ault Lending, LLC(2)
Common Stock 16,686 D
Common Stock 99,619 I By Ault Life Sciences, Inc.(3)
Common Stock 549 I By Ault Life Sciences Fund, LLC(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $3.7368. The range of purchase prices on the transaction date was $3.592 to $3.95 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
2. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Alliance, Inc. ("AAI"). Mr. Ault, the Executive Chairman of AAI, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
3. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
4. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
Remarks:
/s/ Milton C. Ault, III 08/01/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ALZN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALZN

DatePrice TargetRatingAnalyst
10/1/2021$8.00Buy
Ascendiant Capital Markets
More analyst ratings

$ALZN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

    ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with Alzheimer's in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its contract r

    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

    Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with MDD in the fourth quarter of 2025. This study follows t

    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

    ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its contract research

    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALZN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALZN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALZN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALZN
SEC Filings

See more

$ALZN
Leadership Updates

Live Leadership Updates

See more
  • Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

    Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALZN
Financials

Live finance-specific insights

See more
  • BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

    BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)

    $ALZN
    $MICS
    $NILE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Electronic Products
    Consumer Staples
  • BitNile Holdings Reports Second Quarter 2022 Financial Results

    BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi

    $ALZN
    $NILE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials
  • BitNile Holdings Reports 2021 Year-End Results

    The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021

    $ALZN
    $NILE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

$ALZN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more